On August 29, 2025 Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, reported change of date and time of management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time (Press release, Pasithea Therapeutics, AUG 29, 2025, View Source [SID1234655585]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 5:00 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register

On August 29, 2025 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported that senior leadership plans to present at the following conferences (Press release, Iovance Biotherapeutics, AUG 29, 2025, View Source [SID1234655584]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025 Wells Fargo Healthcare Conference
Fireside Chat: September 5, 2025 at 8:00 a.m. ET
Boston, MA
H.C. Wainwright 27th Annual Global Investment Conference
Presentation: September 9, 2025 at 11:00 a.m. ET
New York, NY
The live and archived webcasts will be available at View Source

On August 29, 2025 Bristol Myers Squibb (NYSE: BMY) reported that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 (Press release, Bristol-Myers Squibb, AUG 29, 2025, View Source [SID1234655583]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will take part in a fireside chat beginning at 8:30 a.m. ET.

Investors and the general public are invited to listen to the session by visiting View Source An archived edition of the session will be available following its conclusion.

On August 29, 2025 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in fireside chats at two upcoming investor conferences (Press release, Arvinas, AUG 29, 2025, View Source [SID1234655582]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference on Thursday, September 4. A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company’s website.

Cantor Global Healthcare Conference on Friday, September 5. A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company’s website.

On August 29, 2025 Amgen (NASDAQ:AMGN) reported it will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025 (Press release, Amgen, AUG 29, 2025, View Source [SID1234655581]). Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.